BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 3898370)

  • 1. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of heparin cofactor II by heparin and dermatan sulfate.
    Tollefsen DM
    Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
    Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
    Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082.
    Ofosu FA; Fareed J; Smith LM; Anvari N; Hoppensteadt D; Blajchman MA
    Eur J Biochem; 1992 Jan; 203(1-2):121-5. PubMed ID: 1730217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate.
    Sié P; Fernandez F; Caranobe C; Gabaig AM; Boneu B
    Thromb Res; 1984 Jul; 35(2):231-6. PubMed ID: 6206589
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
    Van Ryn-McKenna J; Gray E; Weber E; Ofosu FA; Buchanan MR
    Thromb Haemost; 1989 Feb; 61(1):7-9. PubMed ID: 2473537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II.
    Yamagishi R; Koide T; Sakuragawa N
    FEBS Lett; 1987 Dec; 225(1-2):109-12. PubMed ID: 3691797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
    Buchanan MR; Brister SJ
    Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
    Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
    Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR; Boneu B; Ofosu F; Hirsh J
    Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.